BRIM Biotechnology, Inc. and Ora, Inc. announce new partnership to accelerate the development of regenerative peptide therapy, BRM421 for Dry Eye Disease

Taipei, Taiwan, May 17th, 2022: BRIM Biotechnology, Inc. (“BRIM”) a clinical-stage company developing novel regenerative therapies in ophthalmology, today announces it has entered into a new strategic partnership with Ora®, Inc. (“ORA”) the world’s leading, ophthalmic research organization, for the late-stage…

Read More